Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Mental Health & Depression — Weekly Report — October 12, 2026

Home/Health Insights/Mental Health & Depression — October 12 – October 19, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Mental Health & Depression
Updated Monday · November 16, 2026
Mental Health & Depression · October 12 – October 19, 2026

Mental Health & Depression
Weekly Report

This week's data 60 new clinical trials registered across 10 countries, with 3,256 trials actively recruiting patients worldwide.
Week of October 12 – October 19, 2026
  • 60 new clinical trials registered across 10 countries.
  • 3,256 trials actively recruiting patients worldwide.
  • Notable trial: Validation and Comparative Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers for the Prevention and E... (3692 patients).
  • 1,677 new research papers published.
  • Top cited: "The relationship between mental health disorders and LUTS." (Autonomic neuroscience : basic & clinical, 2 citations).
  • Drug safety: Most reported effect across tracked medications (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine) was Off Label Use.
  • 8 active drug recall alert(s) — see details below.

The week in numbers

Figures · October 12 – October 19, 2026
New Trials This Week
60.
registered Oct 12–Oct 19
Recruiting Now
3,256
active trials seeking patients
Countries
10
with active trials this week
Papers Published
1,677
new studies this week
Phase 3 Trials
1
late-stage trials this week
Fig. 01

Trials by country

Count · October 12 – October 19, 2026
Turkey (Türkiye)
14
Not specified
9
Chile
7
United States
6
China
3
France
3
United Kingdom
2
Sweden
2
Bangladesh
2
Canada
2
0 4 8 12 14
total
Fig. 02

Trials by phase

Distribution · October 12 – October 19, 2026

New clinical trials registered this week for Mental Health & Depression. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

60 trials registered for Mental Health & Depression. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Artificial Intelligence-Powered Virtual Reality Exposure Therapy for OCD in College Students: A Proof-of-Concept Study Mental Health & Depression · University of California, San Diego (NCT07877363) Other Not Yet Recruiting 24 N/A
02 A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness Mental Health & Depression · Alexandria University (NCT07879131) Other Not Yet Recruiting 60 Bahrain
03 Effects of Preoperative Virtual Reality on Surgical Fear and Anxiety in Patients Mental Health & Depression · Karabuk University (NCT07878039) Other Completed 74 Turkey (Türkiye)
04 Digital Single-Session Cognitive Behavioural Therapy in Healthy Adults Mental Health & Depression · Brunel University (NCT07873905) Other Completed 110 United Kingdom
05 Effect of Spiritual-Based Clinical Hypnotherapy on Maternal Anxiety and Infant Weight Gain Mental Health & Depression · Hasanuddin University (NCT07872618) Other Completed 50 Indonesia
06 A Community-based, Peer-led Counseling Service: A Hybrid Type 3 Effectiveness-implementation Study Mental Health & Depression · St.Gallen University of Applied Sciences (NCT07879443) Other Not Yet Recruiting 65 N/A
07 Effectiveness of Health Communication on Depression Elderly in Ho Chi Minh City Mental Health & Depression · University of Medicine and Pharmacy at Ho Chi Minh City (NCT07877571) Other Recruiting 550 Vietnam
08 Student-Centred Simulation-Based Skills Training on Coping Self-Efficacy, Stress, and Anxiety Among Nursing Students in the UAE Mental Health & Depression · Universiti Sains Malaysia (NCT07871539) Other Not Yet Recruiting 60 United Arab Emirates
09 Feasibility Study of a Co-Designed Gamified Medical Yoga App for Home-Based Cancer Rehabilitation Mental Health & Depression · Linkoeping University (NCT07872956) Other Recruiting 10 Sweden
10 Lifestyle Behaviors and Their Associations With Mental Health, Aggressive Behaviors and Academic Performance Among Assiut University Students Mental Health & Depression · Assiut University (NCT07879248) Other Not Yet Recruiting 579 N/A
11 AI-Assisted Patient Education Before Suturing in Minor Trauma Mental Health & Depression · Gazi University (NCT07872215) Other Recruiting 96 Turkey (Türkiye)
12 Effects of Music on Preoperative Anxiety and Emergence Delirium in Children Mental Health & Depression · Uludag University (NCT07877428) Other Completed 65 Turkey (Türkiye)
13 Climate Change Education Based on the IMB Model for Pregnant Women Mental Health & Depression · Cukurova University (NCT07871032) Other Completed 50 Turkey (Türkiye)
14 Effects of Nurse-Led School-Based Mental Health Education on Beliefs Toward Mental Illness, Social Distance, and Empathy in Adolescents Mental Health & Depression · Neslihan Lok (NCT07879352) Other Completed 72 Turkey (Türkiye)
15 Artistic and Movement Activities to Reduce Anxiety in Children With Acute Lymphoblastic Leukemia. Mental Health & Depression · Children's Cancer Hospital Egypt 57357 (NCT07878065) Phase 3 Recruiting 76 Egypt
16 The Health Literacy for Healthier Mind Study Mental Health & Depression · Molde University College (NCT07878403) Other Not Yet Recruiting 480 N/A
17 Self-Compassion Based Psychoeducation Program for Adolescents With Adverse Childhood Experiences Mental Health & Depression · Ahmet Alkal (NCT07875439) Other Completed 28 Turkey (Türkiye)
18 PREOPERATIVE FASTING AND PERIOPERATIVE OUTCOMES IN CHILDREN UNDERGOING ELECTIVE CIRCUMCISION Mental Health & Depression · Burcu Ayvazoğlu (NCT07876583) Other Not Yet Recruiting 60 N/A
19 Tiny Heroes Compared to Treatment as Usual to Decrease and Prevent Anxiety Problems in Young Children - a Randomized Controlled Study Mental Health & Depression · Karolinska Institutet (NCT07870213) Other Not Yet Recruiting 350 N/A
20 Mindful RAVANS Study Mental Health & Depression · Spaulding Rehabilitation Hospital (NCT07872761) Other Not Yet Recruiting 20 N/A
21 HomeCare Medication Management for People With Dementia Mental Health & Depression · HiDO Technologies (NCT07872072) Other Not Yet Recruiting 120 United States
22 The Effect of Diaphragmatic Breathing Exercises on Pain, Dyspnea, Posture, Body Awareness, Anxiety, and Depression in Young Adults Mental Health & Depression · Alper Kemal Gürbüz (NCT07872163) Other Recruiting 33 Turkey (Türkiye)
23 A Digital Mindfulness-Based Program for OCD Mental Health & Depression · Unidade Local de Saúde de Coimbra, EPE (NCT07871344) Other Not Yet Recruiting 128 N/A
24 Healing Hearts: A Mindfulness App for Parents Navigating Divorce or Separation Mental Health & Depression · University of Connecticut (NCT07871916) Other Recruiting 96 United States
25 MOLI Technique and Virtual Reality Versus Conventional Venipuncture for Pain and Anxiety in Children Mental Health & Depression · José Luis Cobo Sánchez (NCT07878117) Other Completed 201 Spain
26 Testing Interventions to Mitigate the Health Impact of Heatwaves on Primary School Children in Climate-vulnerable Districts of Bangladesh. Mental Health & Depression · BRAC University (NCT07877935) Other Recruiting 2,875 Bangladesh
27 Effects of Progressive Muscle Relaxation on Anxiety, Depression, and Quality of Life in Adults With Type 2 Diabetes Mental Health & Depression · Gul Dural (NCT07876401) Other Completed 80 Turkey (Türkiye)
28 The PSP Alcohol Reset Course Mental Health & Depression · University of Regina (NCT07873684) Other Recruiting 60 Canada
29 Relaxation Exercise Interventions for Individuals Who Have Undergone Urinary Tract Stone Surgery Mental Health & Depression · Ondokuz Mayıs University (NCT07873008) Other Not Yet Recruiting 120 Turkey (Türkiye)
30 SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant Depression Mental Health & Depression · BrainHealth Solutions, Inc. (NCT07876908) Other Recruiting 20 United States
31 4-7-8 Breathing Before Colonoscopy: Effects on Anxiety, Pain, and Embarrassment Mental Health & Depression · Manisa Celal Bayar University (NCT07877012) Other Completed 104 Turkey (Türkiye)
32 Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Mental Health & Depression · Clive Michelsen (NCT07871877) Phase 2 Not Yet Recruiting 60 United States
33 Effects of Binaural Beats on Pain and Anxiety During Flexible Cystoscopy Mental Health & Depression · Saglik Bilimleri Universitesi (NCT07878182) Other Completed 120 Turkey (Türkiye)
34 Effect of Video -Based vs Standard ınformation on Maternal Anxiety and Procedure Decision in Pregnant Woman Offered Amniocentesis or Cvs Mental Health & Depression · Ankara City Hospital Bilkent (NCT07876726) Other Not Yet Recruiting 250 Turkey (Türkiye)
35 Musculoskeletal Discomfort and Ergonomic Factors in Midwifery Students Mental Health & Depression · Mardin Artuklu University (NCT07873567) Other Recruiting 323 Turkey (Türkiye)
36 Cognitive Intervention for Children and Adolescents With NF1 Mental Health & Depression · The Hospital for Sick Children (NCT07869914) Other Not Yet Recruiting 60 N/A
37 Foot Reflexology for Anxiety in Women Hospitalized With High-Risk Pregnancy Mental Health & Depression · Wolfson Medical Center (NCT07878637) Other Not Yet Recruiting 144 Israel
38 Low-intensity Ultrasound for Individuals With Obsessive-compulsive Disorder Mental Health & Depression · University of Calgary (NCT07872917) Other Not Yet Recruiting 20 Canada
39 Comparing 10 Hz rTMS and iTBS for Adolescent Depression Mental Health & Depression · Qilu Hospital of Shandong University (NCT07873060) Other Recruiting 80 China
40 Feasibility and Preliminary Outcomes of Compassion-Focused Group Therapy for Depression and Anxiety Mental Health & Depression · Karolinska Institutet (NCT07876453) Other Completed 21 Sweden
41 Remote Medical Monitoring of Patients With Depression Mental Health & Depression · ThIA Santé Mentale (NCT07878754) Phase 1 Recruiting 608 France
42 Disease Intervention Specialist (DIS) for SUD Mental Health & Depression · Ohio State University (NCT07875361) Other Not Yet Recruiting 1,200 United States
43 Validation and Comparative Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers for the Prevention and Early Detection of Schizophrenia Mental Health & Depression · University Hospital, Aachen (NCT07876089) Other Active Not Recruiting 3,692 Germany
44 Virtual Reality Therapy to Improve Arthroplasty Outcomes Mental Health & Depression · NHS Highland Research, Development and Innovation Organisation (NCT07872670) Other Recruiting 40 United Kingdom
45 Effectiveness of Enhanced Dialectical Behavior Therapy Skills Training Group for Borderline Personality Disorder Mental Health & Depression · Hospital Dr Sotero del Rio (NCT07875166) Other Recruiting 360 Chile
46 Treating Seasonal Depression With Daylight Mental Health & Depression · Klaus Martiny (NCT07877402) Other Not Yet Recruiting 150 Denmark
47 Exploring the Exercise Fear Experiences of Patients With Peripheral Arterial Disease: A Qualitative Study Mental Health & Depression · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (NCT07877129) Other Completed 18 China
48 The Effect of Virtual Reality Use in Cystoscopy on Pain, Anxiety, and Comfort: A Randomized Controlled Trial Mental Health & Depression · Karamanoğlu Mehmetbey University (NCT07872137) Other Completed 63 Turkey (Türkiye)
49 Emotion-Belief Intervention for Subthreshold Depression in College Students Mental Health & Depression · Huazhong University of Science and Technology (NCT07869810) Other Completed 86 China
50 Two Sessions of Coach-Delivered Core Transformation for Distress and Well-Being Mental Health & Depression · Andreas NLP (Legal Entity - Real People Press) (NCT07879196) Other Not Yet Recruiting 480 United States
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Mental Health & Depression. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
sertraline Nausea 958
fluoxetine Off Label Use 508
escitalopram Fatigue 725
venlafaxine Off Label Use 734
duloxetine Off Label Use 667

Recalls & safety notices

§ 05 · 8 items this week

FDA drug recall notices for medications related to Mental Health & Depression. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionU.S Nationwide StatusOngoing
Jul 15
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionNationwide in the US StatusOngoing
Dec 6
2024
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNJ, AZ, IN StatusOngoing
Jul 25
2025
IIClass

DULOXETINE

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

ManufacturerAjanta Pharma Ltd. DistributionNationwide within U.S StatusOngoing
Apr 29
2026
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
§ 06

Published research

1,677 papers

Recently published peer-reviewed studies related to Mental Health & Depression, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Longitudinal associations between dietary intake and common mental disorders among adolescents in Australia. Davidson L et al. 10.1111/camh.70129
View abstract

BACKGROUND: There is a need for more longitudinal research exploring temporal associations between diet quality and common mental disorders (CMDs) during adolescence. This study examined prospective associations between indicators of adolescents' diet quality (fruit, vegetable, sugar-sweetened beverage [SSB] intakes) and risk of depression and anxiety onset over 3 years. We hypothesised that higher fruit and vegetable intake, and lower SSB intake, would be associated with lower risk of CMDs. METHODS: 6537 Australian adolescents (mean age 12.65 years at baseline) completed surveys at baseline, 1-, 2- and 3-year follow-ups. We fitted Generalised Estimating Equations Poisson regression models to assess longitudinal associations between daily servings of fruit, vegetables and SSBs, and risk of depression and anxiety onset (binary cut-points on validated scales) over 3 years. Models were re-run for males and females. Analyses excluded participants who met thresholds for depression or anxiety at baseline to increase confidence that diet predicted CMD onset. RESULTS: Higher fruit intake was associated with lower risk of depression (adjusted RR: 0.87, 95% CI: 0.82-0.93) and anxiety (adjusted RR: 0.93, 95% CI: 0.87-0.99) over 3 years, with limited evidence of sex differences. Higher SSB intake (log-transformed) was associated with higher CMD risk for both sexes, but more strongly for males (depression: adjusted RR: 3.25, 95% CI: 2.02-5.23; anxiety: adjusted RR: 5.50, 95% CI: 3.39-8.90) than females (depression: adjusted RR: 3.10, 95% CI: 2.06-4.68; anxiety: adjusted RR: 2.04, 95% CI: 1.23-3.37). Results inform the Global burden of disease Lifestyle And mental Disorders project (DERR2-https://doi.org/10.2196/65576). CONCLUSIONS: Longitudinal research exposing temporal associations between diet and CMDs may inform prevention/intervention efforts targeting modifiable risk factors for CMDs.

Child and adolescent mental health 2026 Oct 18 PubMed
02 Efficacy and Safety of Integrated Chinese and Western Medicine for Depression With Anxiety and Somatic Symptoms: A Meta-Analysis. Feng Y et al. 10.1177/00912174261494401
View abstract

ObjectiveSomatic symptoms are often linked with depression and anxiety, making diagnosis difficult and limiting treatment effectiveness. Integrated Traditional Chinese and Western medicine has been studied as a complementary approach; however, its efficacy and safety have not been systematically evaluated. This review and meta-analysis examined the effectiveness and safety of integrated Traditional Chinese and Western medicine in patients diagnosed with depression with or without comorbid anxiety and somatic symptoms.MethodsThis systematic review and meta-analysis followed PRISMA 2020 guidelines. English-language studies published from 2014 to 2026 were searched in PubMed, Web of Science, and Scopus. Randomized controlled trials comparing integrated therapy with control interventions were included. The primary outcome was depression severity assessed by HAMD scores. Secondary outcomes included anxiety symptoms, somatic symptoms, and adverse events. A random-effects model was used, and heterogeneity was assessed using the I statistic.ResultsEleven studies met review criteria. Integrated therapy significantly reduced depression severity compared with the standard Western medicine control condition (MD = -3.95, 95% CI: -4.71 to -3.19; I = 59%). Anxiety symptoms were also significantly reduced (MD = -3.95, 95% CI: -4.65 to -3.26; I = 50%). Somatic symptoms, including sleep disturbances and pain-related outcomes, improved but were assessed descriptively because of reporting variability. Adverse events were lower or similar in combined treatment groups, indicating a favorable safety profile. Funnel plot analysis suggested minimal publication bias.ConclusionIntegrated Traditional Chinese and Western medicine was associated with greater improvements in depression and anxiety symptoms than the included control interventions, which comprised Western medicine alone, placebo/sham interventions, or usual care, while showing generally good tolerability. However, given the methodological limitations, heterogeneity of comparator conditions, and low certainty of the available evidence, these findings should be interpreted cautiously.

International journal of psychiatry in medicine 2026 Oct 18 PubMed
03 Frontiers in Neurotransmitter Probes: Innovations and Perspectives in Norepinephrine Detection Technology. Ma R et al. 10.1155/jamc/5515088
View abstract

Norepinephrine (NE), the primary neurotransmitter of locus coeruleus projections, plays a crucial role in regulating arousal, emotion, memory, and stress responses. Its dysregulation is closely associated with various neurological disorders such as depression, Parkinson's disease, and epilepsy. However, conventional detection techniques such as microdialysis coupled with liquid chromatography are constrained by limited spatiotemporal resolution and inherent invasiveness, largely due to NE's low concentration, rapid metabolism, and complex distribution in vivo. These limitations make real-time, in situ dynamic monitoring particularly challenging. In recent years, fluorescence and bioluminescence probe technologies, founded on molecular recognition or self-assembly strategies, have enabled notable advances in the in situ detection and imaging of NE, owing to their superior spatiotemporal resolution, favorable biocompatibility, and versatile design. This review summarizes several representative studies in the field, covering probe design principles, response mechanisms, analytical performance, and biological applications. It also highlights emerging frontiers such as subcellular localization, in vivo dynamic imaging, millisecond-scale monitoring, multitarget cooperative recognition, and integrated diagnosis and therapy. These technologies have deepened our understanding of the spatiotemporal dynamics of NE in physiological and pathological processes, while also providing powerful tools for mechanistic research, early diagnosis, and precise treatment of neuropsychiatric disorders.

Journal of analytical methods in chemistry 2026 PubMed
04 Preliminary Development of a Peer Willingness Scale for Depression and Analysis of Associated Factors Among Chinese College Students: A Cross-Sectional Study. Fu Y et al. 10.1155/da/3448143
View abstract

BACKGROUND: While peer support can alleviate depressive symptoms of college students, peers' willingness to intervene and factors associated with this willingness remain understudied. This study aims to (1) develop and validate a Bystander Intervention Willingness for Depression (BIWD) scale for Chinese college students and (2) identify key sociodemographic and sociopsychological correlates of willingness. METHODS: A cross-sectional study was conducted from May to June 2024. A 13-item BIWD scale based on the Bystander Intervention Model was assessed using exploratory ( = 217) and confirmatory ( = 1008) factor analyses. Linear regression models examined associations between BIWD scores and sociodemographic factors, social perceptions, and mental health indicators. RESULTS: The BIWD scale comprised four dimensions: depression-related cognition, intervention responsibility, bystander effect resistance, and self-efficacy. Older age, higher socioeconomic status, stronger personal anti-stigma attitude, greater interpersonal closeness, and stronger social support were associated with higher BIWD scores. Students with depressive or anxiety symptoms showed higher depression-related cognition, but lower intervention responsibility, self-efficacy, and higher susceptibility to bystander effects. CONCLUSIONS: Findings support the BIWD scale as a useful tool for assessing peer intervention willingness. Initiatives to reduce personal stigma, family functioning enhancement, and targeted self-efficacy training, especially for students experiencing mental health symptoms, may strengthen peer-based support for depression.

Depression and anxiety 2026 PubMed
05 A cross-sectional study of the prevalence and correlates of post-traumatic stress among people attending acceptance and commitment therapy for chronic pain. Kadri K et al. 10.1177/20494637261497966
View abstract

OBJECTIVE: Experiences of trauma are common among people with chronic pain, although estimates of comorbid post-traumatic stress vary widely across contexts. Acceptance and commitment therapy (ACT), which targets psychological flexibility to improve pain-related functioning, is increasingly delivered for people with pain. To inform treatment delivery, understanding of the prevalence and correlates of post-traumatic stress among those attending ACT-based treatment for pain is needed. This study aimed to identify the prevalence of post-traumatic stress and its associations with key pain-related outcomes and other relevant psychosocial factors at the start of an ACT-based treatment. METHODS: This was a cross-sectional study using data collected within routine clinical care at a speciality pain management service in the UK. Four hundred and fifty-one participants completed standardized self-report questionnaires of post-traumatic stress symptoms (PTSS), pain-related outcomes (pain intensity and interference, work and social adjustment, and depression symptoms), psychological flexibility/inflexibility, and stigma at the start of an interdisciplinary ACT-based treatment for chronic pain. RESULTS: Forty-seven percent of patients ( = 213) reported a traumatic exposure and 30% of the sample reported clinically meaningful PTSS. Greater severity of PTSS and probable post-traumatic stress disorder (PTSD) were associated with significantly worse pain-related outcomes, psychological flexibility/inflexibility, and stigma in bivariate analyses. PTSS severity and probable PTSD showed significant unique associations with poorer pain outcomes in regression models controlling for covariates and psychological flexibility/inflexibility. CONCLUSIONS: Post-traumatic stress is common among people engaging in ACT-based treatment for pain and associated with adverse pain outcomes. Trauma-informed practice is therefore important when providing ACT-based treatment for pain.

British journal of pain 2026 Oct 16 PubMed
06 Convergent and Distinct Transcriptional Signatures in Suicide, Bipolar Disorder, and Major Depressive Disorder. Mishra R et al. 10.64898/2026.10.14.759202
View abstract

Globally, a person dies by suicide every 40 seconds, underscoring a major global public health concern. In the United States, suicide is the second leading cause of death among individuals aged 10-34 years. Suicide is a complex, multifactorial phenomenon influenced by genetic and epigenetic factors and is strongly associated with mood disorders, particularly major depressive disorder (MDD) and bipolar disorder (BD). However, the extent to which their molecular signatures converge or diverge across disorders and brain regions remains incompletely understood. To address this gap, we conducted a systematic literature review of suicide, MDD, and BD transcriptomic studies in accordance with PRISMA 2020 guidelines, searching PubMed, Embase, and Web of Science. Eligible studies used human postmortem brain tissue, reported a complete genome-wide transcriptomic list of differentially expressed genes (DEG), and compared suicide decedents with psychiatric non-suicide individuals diagnosed with the same underlying disorder. Regarding BD, studies comparing affected individuals to unaffected controls were included. Single-cell and peripheral-blood studies were excluded because unavailable for suicide. Curated suicide and BD DEG datasets were integrated with a published bulk transcriptomic dataset of MDD. We identified both shared and disease-specific molecular signatures across suicide, BD, and MDD, and identified DEGs shared across brain regions and those that were region-specific. A total of 276 genes were shared across all three conditions, implicating cellular stress, hypoxia (VEGFA, ADM, NDRG1, DDIT4), immune and inflammatory signaling through TNFα/NF-κB (IL1B, ICAM1, NFE2L2) and IL6-JAK-STAT3 pathways (STAT3, SOCS3, IL1R1m OSMR), complement activation (CIR, SERPiNA1, LGALS3), extracellular matrix remodeling (COL4A1, SERPINH1, PLOD2), and unfolded protein response (BAG3, WFS1, MTHFD2). Suicide-associated DEGs were prominently downregulated, and involved metal-ion homeostasis, stress responses, synaptic regulation, and circadian pathways, whereas BD showed downregulation in synaptic and vesicle-related processes alongside region-specific metabolic dysregulation. MDD exhibited changes in RNA processing, ribosomal function, and protein synthesis. Genetic integration revealed that 133 genes shared between BD and MDD had gene variants associated with the corresponding condition per GWAS. Transcription factor analysis identified 20 regulatory factors with altered activity across all three conditions despite differences in their predicted downstream targets. Overall, these findings suggest that suicide, MDD, and BD share aspects of their molecular and regulatory pathophysiology while exhibiting distinct patterns, including in a region-specific manner.

bioRxiv : the preprint server for biology 2026 Oct 15 PubMed
07 Comparative Effects of Psychosocial and Behavioral Interventions to Prevent or Reduce Suicidal Ideation and Suicidal Behavior: A Network Meta-Analysis. Nguyen TN et al. 10.1177/00207640261496219
View abstract

BACKGROUND: Previous meta-analyses combined treatment with prevention interventions and there was a lack of comparative studies on preventive interventions for suicide. AIMS: To evaluate and rank the effects of prevention interventions on self-harm, suicidal ideation, suicidal behavior, and depression. METHODS: We searched PubMed, HINARI, CENTRAL and ResearchGate until November 2025 to identify randomized controlled trials that reported suicidal ideation and suicidal behavior among adolescents and adults. Eligible studies were selected through systematic screening, and data were synthesized using a network meta-analysis with a random-effects model to assess and rank effects of psychosocial and behavioral interventions in January 2026. RESULTS: This study included 94 trials (27,242 participants). Compared with control group, psychotherapy ( = 0.60; 95% CI [0.47, 0.76]), active outreach ( = 0.73; 95% CI [0.59, 0.90]), and other psychosocial and behavioral interventions (hereafter, "other type"; = 0.53; 95% CI [0.33, 0.86]) were the three most effective interventions in preventing suicidal behavior (moderate-quality evidence). Psychotherapy (Standardized mean difference [SMD] = -0.18; 95% CI [-0.31, -0.05]; moderate-quality evidence) and other type (SMD = -0.60; 95% CI [-0.86, -0.33]; moderate-quality evidence) were the two most effective interventions in preventing suicidal ideation. Only psychotherapy was significantly more effective than control group ( = 0.66; 95% CI [0.48, 0.91]; moderate-quality evidence) in reducing self-harm. Only skills showed effectiveness in reducing depression with very low-quality evidence (SMD = -0.67; 95% CI: [-1.07, -0.28]). CONCLUSIONS: Psychotherapy consistently improved several suicide-related outcomes, indicating that clinical and community settings should prioritize this intervention. Healthcare policymakers and practitioners should integrate psychotherapy into regular mental health services and expand active outreach activities to improve conditions and use of the beneficiaries.

The International journal of social psychiatry 2026 Oct 17 PubMed
08 HIV-related stigma and self-management in young people living with HIV in rural South Africa: a socioecological perspective. Majee W et al. 10.1177/17579759261485207
View abstract

Despite progress toward UNAIDS 95-95-95 targets, HIV-related stigma continues to undermine self-management and health outcomes, particularly in rural areas. This study explored how stigma influences self-management among young people living with HIV (YPLHIV) in rural South Africa, applying a socioecological model to examine individual, social, institutional, and structural factors shaping health behaviors and cognitive functioning. Twenty interviews were conducted with YPLHIV aged 18-35 years. Data were thematically analyzed. Participants described intense internalized stigma and fear following diagnosis, often leading to shame, isolation, or suicidal ideation. Counseling, health education, and treatment success promoted self-efficacy and acceptance, enabling adherence and future-oriented goals. Family and caregiver support fostered resilience, while peer rejection reinforced stigma. Positive relationships with healthcare providers encouraged adherence, though gaps in communication around viral load and CD4 monitoring were noted. At the structural level, supportive health policies, free antiretroviral treatment, and routine testing enabled early diagnosis and treatment, but poverty and unemployment limited the ability to maintain healthy lifestyles. HIV-related stigma profoundly shapes the psychosocial well-being and self-management behaviors of YPLHIV. Interventions that strengthen self-efficacy, mental health support, and coping strategies, while simultaneously addressing family, community, and structural contexts, are essential to reduce the stigma's impact and promote sustained engagement in care.

Global health promotion 2026 Oct 17 PubMed
09 Greening, Violence Exposure, and Adolescent Mental Health: The Role of Perceived Neighborhood Greening, Neighborhood Aesthetics, and Harmful Urban Conditions. Fix RL et al. 10.1007/s11524-026-01175-y
View abstract

Neighborhood environments influence adolescent health. Vacant lots and violence exposure contribute to elevated mental health risks, particularly for Black youth, cisgender girls, and transgender or gender non-conforming youth. Urban greening shows promise for improving safety, community cohesion, and adolescent mental health; however, most existing evidence comes from adult-focused studies, underscoring the need to better understand its effects on youth. In response, we examined whether perceptions of neighborhood greening and maintenance are associated with the mental health impacts of violence exposure among adolescents living in Baltimore City. We recruited adolescents aged 14-19 from Baltimore City to participate in Project VITAL. Young people completed in-person surveys at youth-focused community events between October 2022 and September 2023 after obtaining appropriate consent and assent. We found that violence exposure was consistently associated with PTSD, depression, anxiety, and reduced happiness for Black adolescents in Baltimore. Nearby greening conditions did not lessen these effects. However, certain facilitators of green space use (e.g., more trees in the neighborhood, access to green spaces) were linked to increased happiness, as well as lower depression and anxiety. Overall, neighborhood greening alone appears insufficient to promote mental health without broader investments in safety, stability, and youth-centered supports. To promote mental well-being, findings indicate that greening would need to be combined with other evidence-based strategies to improve adolescent safety and mental well-being.

Journal of urban health : bulletin of the New York Academy of Medicine 2026 Oct 17 PubMed
10 Differential Cerebral Perfusion Patterns Across Migraine Phenotypes: An Exploratory ASL MRI Study. Hu Y et al. 10.1016/j.acra.2026.09.073
View abstract

RATIONALE AND OBJECTIVES: This study aims to characterize cerebral blood flow (CBF) alterations across migraine phenotypes and determine whether perfusion measures provide additional information for phenotype differentiation. MATERIALS AND METHODS: The final cohort comprised 143 patients with migraine and 49 healthy controls who underwent three-dimensional pseudo-continuous arterial spin labeling (ASL) MRI. Voxel-wise analyses of normalized CBF (nCBF) were performed to identify phenotype-related perfusion alterations. Sensitivity analyses repeated the voxel-wise comparisons with phenotype-appropriate clinical covariates. Exploratory correlation analyses examined associations between regional perfusion and clinical characteristics. Logistic regression was further used to assess whether perfusion measures provided additional information for differentiating migraine with aura (MA) from migraine without aura (MO). RESULTS: Compared with healthy controls, migraine patients with depressive symptoms showed reduced nCBF in a right hippocampus-parahippocampal cluster (Cluster 1) in the primary voxel-wise analysis; however, this finding did not survive additional adjustment for sleep quality. Lower Cluster 1 nCBF was associated with greater headache frequency. Compared with MO, patients with MA showed increased nCBF in a right cerebellar-occipitotemporal cluster peaking in the right cerebellar Crus I (Cluster 2), and this difference remained significant after additional adjustment for sleep quality, medication-overuse headache status, and preventive medication exposure. Within the MA group, higher Cluster 2 nCBF was associated with greater headache intensity. In exploratory logistic regression analysis, the combined clinical-imaging model showed a higher apparent area under the curve (AUC) than the clinical model alone. CONCLUSION: Clinically relevant migraine phenotypes showed distinct patterns of regional cerebral perfusion. These findings highlight the importance of considering clinical heterogeneity in migraine neuroimaging and suggest that ASL-derived perfusion measures may provide complementary biological information for phenotype characterization, particularly with respect to aura status.

Academic radiology 2026 Oct 17 PubMed
11 Cannabidiol attenuates behavioral impairments and deficits in parvalbumin interneurons and their perineuronal nets induced by adolescent stress in adult mice. Lima TSA et al. 10.1016/j.pnpbp.2026.111981
View abstract

Adolescence is a critical period for the development of neural circuits, and exposure to stressors during this stage constitutes a risk factor for psychiatric disorders. Previous studies have shown that adolescent stress in rodents leads to behavioral alterations and functional loss of parvalbumin-containing GABAergic (PV+) interneurons and their perineuronal nets (PNNs) in the medial prefrontal cortex (mPFC) and ventral hippocampus (vHip). Although less explored, somatostatin-expressing (SST+) interneurons may also be impaired. Given the reported anti-stress effects of cannabidiol (CBD) in adult rodents, we investigated whether CBD attenuates adolescent stress-induced alterations. Male C57BL/6 J mice were exposed to footshock stress from postnatal day (PND) 31-40 and subsequently received CBD (30 mg/kg, i.p.) for ten days (PND 41-50). After a 15-day drug-free period, animals started being evaluated in adulthood using behavioral assays for anxiety (elevated plus maze, light-dark box), sociability (social interaction), social memory (social discrimination), and cognition (novel object recognition). Adolescent stress impaired social discrimination and object recognition memory, and CBD attenuated these deficits, while sociability and anxiety-like behavior remained unaffected. Consistent with the behavioral findings, stressed animals exhibited reductions in PV+, PNN+, and PV+/PNN+ cells in the mPFC and vHip, as well as a less marked reduction in SST+ cells in the vHip, and CBD attenuated these stress-induced cellular alterations. Our findings suggest that CBD may attenuate behavioral and molecular alterations associated with adolescent stress exposure, particularly those involving PV+ interneurons and their PNNs, highlighting its potential to mitigate stress-induced deficits.

Progress in neuro-psychopharmacology & biological psychiatry 2026 Oct 17 PubMed
12 Potential Mechanisms of N-Methyltyramine in Multitarget Regulation of Mental Disorders via the GPCR-cAMP Pathway. Zijian W 10.1016/j.brainresbull.2026.112169
View abstract

N-Methyltyramine (NMT) is a tyramine derivative widely distributed in citrus plants and the traditional Chinese medicine Zhishi. Pharmacological studies have confirmed that NMT directly binds to the dopamine D₂ receptor (DRD2; Ki = 31.3µM), inhibits forskolin-induced cAMP accumulation (EC₅₀ ≈ 4µM, Emax = 89%), and dose-dependently antagonizes quinpirole-mediated β-arrestin2 recruitment, exhibiting G protein-biased agonistic properties. Meanwhile, NMT activates the human trace amine-associated receptor 1 (hTAAR1; EC₅₀ ≈ 2µM) to increase cAMP, possesses α₂-adrenergic receptor antagonistic activity (IC₅₀ = 5.53µM), and exhibits blood-brain barrier permeability (logPe = -5.16cm/s). Based on these multi-target receptor profiles, NMT may participate in the regulation of central monoaminergic neurotransmission via the GPCR-cAMP signaling axis, providing a new multi-target lead compound direction for research on neurological disorders such as Alzheimer's disease, depression, and drug addiction. Notably, evidence for direct activation of β₂-adrenergic receptors by NMT remains insufficient, and its therapeutic effects and downstream signal integration mechanisms require NMT-specific experimental validation.

Brain research bulletin 2026 Oct 17 PubMed
13 Cholinergic-Dependent Metaplasticity in the Amygdala-Insula Pathway During Incubation of Cocaine Craving. Salin A et al. 10.1016/j.neuropharm.2026.111232
View abstract

The time-dependent increase in drug seeking during abstinence, termed 'incubation of craving' is believed to play a major role in the persistent risks of relapse. This phenomenon is associated with synaptic plasticity changes across brain structures involved in reward processing, executive functions, emotion regulation and inhibitory control. The basolateral amygdala (BLA) and the anterior insular cortex (aIC) are two interconnected structures involved in processing internal and external drug-related cues and are known to play a role in drug craving. However, whether chronic cocaine alters synaptic plasticity within the BLA-aIC circuit and how these changes evolve during abstinence remains unclear. Here, using cocaine self-administration and in vivo electrophysiological recordings in anesthetized male rats, we demonstrate that, while long-term potentiation in the BLA-aIC pathway remains intact, long-term depression is disrupted throughout abstinence in both cocaine- and sucrose-rats, indicating a persistent impairment in synaptic weakening mechanisms. Importantly, a loss of depotentiation was observed after late but not early abstinence, and was specific to cocaine self-administration, identifying it as a hallmark of incubation of craving. Systemic, but not local intra-aIC, blockade of muscarinic receptors with atropine restored depotentiation and reduced cocaine-seeking behavior. Finally, qPCR analysis revealed region-specific transcriptional adaptations, with upregulation of muscarinic, NMDA and AMPA receptor transcripts in the BLA and a selective decrease of Grin2a in the aIC. Together, these findings point to cholinergic regulation of BLA-aIC metaplasticity as a candidate mechanism underlying incubation of cocaine craving.

Neuropharmacology 2026 Oct 17 PubMed
14 Maternal piromelatine treatment is associated with attenuated behavioral alterations and sex-specific changes in hippocampal pCREB/BDNF signaling in adult offspring following prenatal constant-light exposure. Stoyanova T et al. 10.1016/j.bbr.2026.116539
View abstract

Maternal exposure to constant light during pregnancy (CLE) is associated with disrupted circadian organization and persistent behavioral alterations in adult offspring. This study examined behavioural performance and 24-hour locomotor activity patterns, as well as hippocampal pCREB and BDNF levels, in adult male and female offspring following prenatal CLE and maternal treatment with piromelatine (pir), which acts as an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Pregnant Wistar rats under light-dark regime received vehicle (veh), whereas dams exposed to CLE received vehicle (LL-veh), pir (10mg/kg), or melatonin. Compared to the LL-veh groups, offspring from pir-treated dams exhibited reduced anxiety- and depression-like responses and improved working memory in both sexes. Individual-subject cosinor analysis revealed heterogeneous 24-hour locomotor rhythmicity within and between groups. No significant treatment-group effect was detected for MESOR or amplitude, and the descriptive acrophase patterns did not provide evidence of treatment-induced restoration or normalization of circadian organization. Maternal pir treatment was associated with higher hippocampal pCREB and BDNF levels in male, but not female offspring relative to the LL-veh group. While the behavioral and molecular differences occurred concurrently in males, these findings do not prove that pCREB/BDNF signaling mediated the behavioral outcomes. Furthermore, the study cannot distinguish the direct developmental effects of maternal pir exposure from those mediated through maternal or offspring circadian rhythm. Therefore, the findings should be interpreted as long-term behavioral and sex-specific molecular differences associated with maternal pir treatment rather than as evidence of circadian-independent antidepressant, anxiolytic, cognitive-enhancing, or BDNF-enhancing actions.

Behavioural brain research 2026 Oct 17 PubMed
15 A Reproducible Safety Assessment Model for Concurrent Transcranial Magnetic Stimulation with Implanted Intracranial Electroencephalography Electrodes. Chang A et al. 10.1016/j.brs.2026.103238
View abstract

BACKGROUND: Concurrent transcranial magnetic stimulation and intracranial EEG (TMS-sEEG) offers a powerful approach for interrogating human brain circuits with high spatiotemporal resolution. However, standardized safety testing procedures for TMS in the presence of implanted electrodes are lacking. OBJECTIVE: To establish and validate a reproducible methodological framework for assessing TMS safety with sEEG hardware, addressing potential risks of electrode displacement, heating, and secondary current induction. METHODS: A conductive agarose phantom implanted with clinical-grade platinum sEEG electrodes was exposed to single-pulse TMS (0.4 Hz), repetitive TMS (1-50 Hz), and intermittent theta burst stimulation. Electrode displacement was quantified via high-speed video and motion tracking. Temperature changes were measured with fiber-optic thermal probes positioned at stimulated electrode contacts. Induced voltages were recorded using an oscilloscope and intracranial EEG hardware, and secondary current and charge density were calculated from oscilloscope outputs and impedance measurements. RESULTS: sEEG lead displacement remained micrometer-scale across stimulation conditions, with a maximum transient displacement of 10.99 μm and a maximum 1-s mean displacement from the pre-TMS position of 16.27 μm. Temperature changes remained well within the 2°C safety threshold across all tested conditions; in the primary temperature series, the maximum observed increase was 0.073°C. Induced voltages and charge densities remained below established safety limits, exhibiting consistent exponential decay with increasing distance from the coil. All stimulation conditions, including those exceeding typical clinical ranges, remained well within safety margins. CONCLUSIONS: Under the tested conditions in a controlled phantom environment, TMS exposure produced micrometer-scale transient and longer-timescale displacement, temperature changes within established safety thresholds, and charge densities within established safety thresholds. This validated methodological pipeline provides a standardized framework for future safety experiments involving TMS and implanted devices and supports continued development of TMS-sEEG as a tool for studying human brain circuitry and neuromodulation.

Brain stimulation 2026 Oct 17 PubMed
16 The dynamic interplay between subjective and objective cognitive performance and their impact on the prognosis of major depressive disorder: A cross-lagged panel network analysis. Zhang Q et al. 10.1016/j.jad.2026.122642
View abstract

BACKGROUND: Subjective cognitive impairments are highly prevalent in patients with major depressive disorder (MDD) and, consistent with objective cognitive impairments, are associated with greater symptom severity and poorer treatment outcomes. However, their interactions and shared and distinct contributions to depressive symptoms and acute-phase clinical course remain poorly understood. METHODS: We analyzed 621 patients with MDD at baseline and 373 at Week 8. Treatment comprised usual care in a real-world cohort and antidepressant therapy with perospirone or placebo augmentation in a randomized, double-blind trial. Cross-sectional and cross-lagged networks integrated subjective cognition, objective cognition, and three selected depressive symptom domains. Remission-stratified and sensitivity analyses were conducted. RESULTS: Subjective cognition, objective cognition, and depressive symptoms formed distinct interacting modules at both assessments, with global network strength increasing from baseline to Week 8 (ΔS = 0.65, Holm-adjusted p = 0.01). Subjective executive function was most central in non-remitters and objective processing speed in remitters. Accounting for baseline network variables, better baseline subjective executive function was associated with greater Week 8 energy (β = 0.11), and better baseline subjective memory with greater energy and general interest (both β = 0.06). In contrast, better baseline objective immediate verbal memory was prospectively associated with worse Week 8 levels for sad mood, energy/fatigability, and general interest (β = -0.12, -0.07, and - 0.05, respectively). CONCLUSIONS: Subjective and objective cognition showed distinct associations with symptom course, supporting their combined assessment. Better baseline objective memory did not necessarily indicate fewer residual symptoms, but this association does not establish reduced treatment efficacy.

Journal of affective disorders 2026 Oct 17 PubMed
17 Altered resting-state EEG microstate dynamics are associated with auditory hallucinations in patients with major depressive disorder. He Y et al. 10.1016/j.jad.2026.122626
View abstract

BACKGROUND: Auditory hallucination experiences are an understudied but clinically significant feature of major depressive disorder (MDD). Although EEG microstate abnormalities have been reported in MDD, their relationship with auditory hallucination experiences remains unclear. This study investigated resting-state EEG microstate dynamics associated with auditory hallucination experiences in first-episode MDD. METHODS: A total of 182 first-episode patients with MDD and 95 healthy controls underwent resting-state EEG recordings. Patients were classified according to lifetime history of auditory hallucination experiences into those with (AH+, n = 42) and without (AH-, n = 140) such experiences. Patients were either psychotropic medication-naïve or minimally medicated (<2 weeks of cumulative exposure). Microstate parameters were compared among groups. ANCOVA and hierarchical binary logistic regression were performed to examine associations with auditory hallucination experiences. RESULTS: Only microstate C occurrence was significantly higher in the AH+ group than in both the AH- and healthy control groups after multiple-comparison correction. This difference remained significant after adjustment for age, sex, education, and depression severity. Hierarchical logistic regression showed that higher microstate C occurrence was independently associated with auditory hallucination experiences (OR = 1.773, 95% CI: 1.211-2.595, p = 0.003), but not with hallucination severity. Its discriminatory ability was modest (AUC = 0.614, 95% CI: 0.516-0.711). CONCLUSIONS: In first-episode MDD, a lifetime history of auditory hallucination experiences was associated with increased microstate C occurrence. This finding suggests that altered microstate C dynamics may represent an electrophysiological correlate of auditory hallucination experiences, warranting further investigation.

Journal of affective disorders 2026 Oct 17 PubMed
18 Childhood trauma dimensions in major depressive disorder: associations with symptoms, inflammation, cognition, and 12-week change. Zhang B et al. 10.1016/j.jad.2026.122645
View abstract

OBJECTIVE: Childhood trauma is associated with major depressive disorder (MDD), but whether specific trauma dimensions show distinct clinical, biological, cognitive, and longitudinal correlates remains unclear. This study examined associations of childhood trauma dimensions with symptom domains, peripheral inflammation, executive cognitive performance, and short-term symptom change in patients with MDD. METHODS: This case-control and follow-up study included 73 patients with MDD and 60 healthy controls. Childhood trauma was assessed using the Childhood Trauma Questionnaire (CTQ). Baseline clinical symptoms, peripheral inflammatory markers, and Wisconsin Card Sorting Test (WCST) performance were evaluated. PHQ-9, GAD-7, and ISI scores were assessed during 12 weeks of follow-up. Cross-sectional associations were examined using Spearman correlations with false discovery rate (FDR) correction. Linear mixed-effects models using observed follow-up data were used as the primary longitudinal analyses. Baseline-adjusted 12-week LOCF endpoint models were conducted as sensitivity analyses, with FDR correction applied across the 15 CTQ-outcome tests. RESULTS: Patients with MDD had higher CTQ total and all five subscale scores than healthy controls. Within the MDD group, emotional abuse remained associated with higher PHQ-9 and GAD-7 scores after FDR correction, whereas physical abuse remained associated with higher ISI scores. No robust associations were identified between CTQ dimensions and peripheral inflammatory markers or WCST measures after multiple-comparison correction. The primary mixed-effects analyses showed no significant baseline-adjusted CTQ main effects or visit-by-CTQ interactions. In the LOCF sensitivity analyses, emotional neglect remained associated with a lower 12-week ISI score after FDR correction (q = 0.035), whereas the physical-neglect-PHQ-9 association did not remain significant (q = 0.320). CONCLUSION: Several childhood trauma dimensions were associated with baseline self-reported symptom severity, but the observed pattern does not establish symptom-specific effects. No robust associations were identified with peripheral inflammation, WCST performance, or longitudinal symptom trajectories. The emotional-neglect-ISI association observed in the LOCF sensitivity analysis was not clearly replicated in the primary mixed-effects analysis and should be considered exploratory.

Journal of affective disorders 2026 Oct 17 PubMed
19 Multidimensional Clinical Benefits of Cinnamon Leaf Oil Inhalation in Primary and Metastatic Brain Tumor Patients During Winter: A Randomized Controlled Trial. Zhang Q et al. 10.1016/j.ctim.2026.103449
View abstract

OBJECTIVE: To evaluate the multidimensional efficacy of 12‑week cinnamon leaf oil (CLO) inhalation as a seasonal adjuvant supportive‑care intervention for alleviating winter‑exacerbated non‑motor symptom burden and improving mood disorders, sleep quality, refractory fatigue, and functional independence in patients with primary and metastatic brain tumors. METHODS: This randomized, controlled clinical trial enrolled 328 patients diagnosed with primary or metastatic brain tumors, randomly assigned at a 1:1 ratio to intervention group (standard antitumor care plus 12‑week undiluted CLO inhalation, 2h/day, 5 days/week, n=165) or control group (standard care plus distilled‑water‑vapor sham‑aromatherapy control, n=163). Baseline demographic and clinical characteristics were descriptively summarized for both groups. The primary outcome was the change in HAM-D total score from baseline to week 12. Secondary outcome indicators included changes in anxiety (HAM‑A), sleep quality (PSQI), physical/mental fatigue (FS-14), and activities of daily living (ADL-BI). Integrated multidimensional outcome profiling was further performed to examine changes across six clinical domains. RESULTS: Twelve weeks of CLO inhalation was associated with improvements across the assessed outcome measures, whereas the control group receiving only standard care showed minimal clinical changes. The intervention group showed reductions in emotional symptoms, with HAM‑A scores decreasing from 17.65±4.48 to 12.25±4.51 (p<0.001) and HAM‑D scores declining from 22.10±5.41 to 13.68±2.71 (p<0.001). Improvements in sleep quality were observed, with PSQI total scores dropping from 12.18±3.05 to 5.25±1.86 (p<0.01). Additionally, the CLO group showed changes in functional independence, with ADL‑BI total scores increasing from 63.60±14.16 to 74.88±11.33 (p<0.01). In terms of fatigue relief, the proportions of patients with severe physical and mental fatigue decreased by 46% and 76%, respectively (p<0.01). Multidimensional profiling indicated favourable changes for CLO inhalation across sleep, anxiety, depression, physical fatigue remission, mental fatigue remission and daily function. Only mild Grade 1 transient mucosal irritation adverse events occurred in the intervention group with low incidence; no severe adverse reactions or trial withdrawal were observed. CONCLUSION: Findings from this single‑centre trial suggest that 12‑week standardized CLO inhalation may represent a tolerable non‑pharmacological adjuvant approach for brain tumour patients. It was associated with reductions in winter‑exacerbated anxiety, depression, sleep disturbance, and refractory fatigue, as well as improvements in patients' functional independence. Observations of multi‑domain symptom changes warrant further clinical investigation to evaluate its utility within neuro‑oncological supportive‑care practice and patients' long‑term quality‑of‑life outcomes.

Complementary therapies in medicine 2026 Oct 17 PubMed
20 Perceived social support and mental health among shidu parents: The moderating role of stigma following the loss of an only child. Li J et al. 10.1080/07481187.2026.2748875
View abstract

Perceived social support is a psychosocial resource that protects the mental health of parents who have lost an only child (shidu parents), but its benefits likely vary depending on stigma-a challenge that these parents face in social contexts. We used data from 482 shidu parents ( = 66.63, = 6.88) who reported perceived support (overall and by specific source, family, peer, and others), depressive symptoms, perceived stigma, and demographic characteristics. Linear regressions showed that family support and others support were negatively associated with depressive symptoms, consistent with the finding for overall perceived support, whereas peer support was not in the main-effect analysis. Perceived stigma consistently moderated associations with depressive symptoms across overall and source-specific support: social support was negatively associated with depressive symptoms when stigma was low, but not when stigma was high. These findings refine our understanding of social support and inform stigma-reduction to maximize its psychological benefits for shidu parents.

Death studies 2026 Oct 17 PubMed
21 Psychological determinants of pain, fatigue, and symptom burden in breast cancer survivorship. Madaminova N et al. 10.1016/j.ctarc.2026.101488
View abstract

Breast cancer survivors frequently experience persistent pain, cancer-related fatigue, and interconnected symptom clusters that impair quality of life, functional status, and treatment adherence. Psychological factors, including pain catastrophizing, anxiety, depression, fear-avoidance behaviors, and maladaptive cognitive appraisals, are associated with the amplification and maintenance of these symptoms through proposed mechanisms involving central sensitization, HPA axis dysregulation, inflammatory signaling, and behavioral deconditioning. This narrative overview, rather than a systematic review, examines these determinants primarily in post-treatment survivorship, defined as the period following completion of surgery, chemotherapy, and radiotherapy and including patients continuing adjuvant endocrine therapy; evidence from active treatment and metastatic disease is identified by treatment phase where drawn upon. Persistent pain is reported by an estimated 25-60% of survivors, and pooled severe post-treatment fatigue by 26.9%, with estimates varying substantially by case definition. Persistent pain has multiple clinically distinct causes, including post-mastectomy pain syndrome, shoulder and myofascial disorders, lymphedema, radiation fibrosis, chemotherapy-induced neuropathy, and endocrine therapy-associated musculoskeletal pain; several of these are correctable, and their evaluation should precede psychological attribution. Psychological predictors are consistently identified but modest in magnitude and operate alongside rather than in place of surgical and disease-stage determinants. Cognitive behavioral therapy for insomnia shows large effects on insomnia severity with concurrent fatigue and mood benefit; mindfulness-based interventions show small pooled effects on distress. Symptom burden and access to intervention remain disproportionately worse among younger patients, those with metastatic disease, and underserved populations.

Cancer treatment and research communications 2026 Oct 17 PubMed
22 Duration of depressive symptoms prior to a cancer diagnosis and post-cancer memory function and decline: A longitudinal analysis of the US Health and Retirement Study. Westrick AC et al. 10.1016/j.jgo.2026.104653
View abstract

INTRODUCTION: Depressive symptoms are associated with increased risk for cognitive decline in the general population, but less is known about how depressive symptoms might influence cognitive aging after a cancer diagnosis in mid-to-later life. We aimed to determine if the duration of depressive symptoms before a cancer diagnosis is associated with post-cancer diagnosis memory function and decline. MATERIALS AND METHODS: Data were from 425 adults aged ≥50 with an incident cancer diagnosis from 2004 to 2020 and three waves of depression data prior to their diagnosis in the US Health and Retirement Study. Depressive symptoms were measured biennially using the Center for Epidemiologic Studies Depression Scale (CESD; range 0 to 8); a score of ≥3 was considered clinically relevant depressive symptoms. Duration of pre-cancer diagnosis clinically relevant depressive symptoms was categorized as never, 1 time point, or ≥ 2 time points. Episodic memory was assessed from the time of cancer diagnosis as a composite of immediate and delayed recall scores. Multivariable adjusted linear mixed-effects models estimated the association between pre-diagnosis depression duration and post-diagnosis memory function and decline. RESULTS: The mean baseline age was 68.9 years (SD: 8.6) and 52.7% were female. In the three survey waves (~6 years) prior to diagnosis, 56.7% (241/425) had no depressive symptoms, 20.0% (85/425) had depressive symptoms at 1 time point, and 23.3% of participants (99/425) had depressive symptoms at ≥2 time points. The mean follow-up time after cancer diagnosis was 6.2 years (SD = 4.7). A longer duration of pre-diagnosis depression was associated with a faster rate of memory decline post-diagnosis (-0.12 SD units/year, 95% CI: -0.22, -0.02). DISCUSSION: Increased duration of depressive symptoms prior to cancer diagnosis is associated with faster memory decline post-cancer diagnosis and may be a salient risk factor for accelerated memory aging among older cancer survivors.

Journal of geriatric oncology 2026 Oct 17 PubMed
23 Time spent, not use frequency: Associations between social media use and anxiety and depressive symptoms across age groups in the Czech population. Moravec V et al. 10.1016/j.actpsy.2026.107985
View abstract

Social media use may facilitate connection and access to information while also being associated with poorer mental health. This study examined associations between social media use and anxiety and depressive symptoms across age groups in the Czech population aged 16 years and older. Cross-sectional data were collected through a computer-assisted web survey conducted in January 2025 among 2867 respondents aged 16 years and older. Anxiety and depressive symptoms were assessed using the GAD-7 and PHQ-9 scales. Internal consistency was high (GAD-7: α = 0.914, ω = 0.916; PHQ-9: α = 0.877, ω = 0.883), and confirmatory factor analysis supported correlated but distinct anxiety and depressive-symptom factors. The original quasi-Poisson and Kruskal-Wallis analyses were retained, while the extended analysis added structural equation modelling (SEM), HC3-robust regression, formal age-interaction tests, and survey-weighted sensitivity analyses. In the primary SEM (n = 1758), longer daily social media use was independently associated with higher latent anxiety (β = 0.155, p < .001) and depressive symptoms (β = 0.138, p < .001), whereas use frequency was not independently associated with either outcome. Profile visibility and perceived societal influence of social media showed no consistent adjusted associations. Age-stratified estimates suggested weaker time-anxiety associations among respondents aged 65 years and older, but formal interaction tests did not confirm significant age moderation. The findings indicate that duration of exposure may be more consistently associated with anxiety and depressive symptoms than use frequency. Because the design is cross-sectional, causal direction cannot be established, and reverse or reciprocal relationships between social media use and mental-health symptoms remain possible.

Acta psychologica 2026 Oct 17 PubMed
24 An evaluation of the longitudinal, bidirectional association between processing speed and self-reported physical functioning in middle-aged and older adults. Imani H et al. 10.1016/j.actpsy.2026.107988
View abstract

BACKGROUND: Previous research shows a complex, bidirectional relationship between cognitive performance and physical functioning in older adults, but the direction and strength over time remain unclear. OBJECTIVE: This study examined longitudinal association between processing speed and physical function, focusing on which domain more strongly influence the other. METHODS: Cross-lagged panel models were estimated using data from waves 4, 5, and 6 of the German Aging Survey, including 2715 middle aged and older participants (aged 40+) living in private households in Germany. Cognitive performance was assessed as processing speed via the Digit Symbol Substitution Test and self-reported physical function via the SF-36 physical functioning subscale Health Survey. The final adjusted model controlled for baseline age, sex, education, depressive symptoms, and chronic disease burden. RESULTS: The adjusted model showed small bidirectional longitudinal associations between processing speed and physical functioning. Physical functioning predicted later processing speed across both time intervals. Processing speed predicted later physical functioning from T1 to T2, whereas the T2 to T3 association was attenuated to marginal significance after covariate adjustment. Sensitivity analyses supported the overall robustness of these modest associations. CONCLUSIONS: Processing speed and self-reported physical functioning show modest bidirectional longitudinal coupling across later adulthood. These findings highlight the importance of considering cognitive performance and physical functioning together when studying aging-related functional decline, independence, and quality of life.

Acta psychologica 2026 Oct 17 PubMed
25 Social appearance anxiety and adult picky eating: Associations with sleep quality, depressive symptoms, and body mass index. Akbay GD et al. 10.1016/j.actpsy.2026.108023
View abstract

BACKGROUND: Although adult picky eating has traditionally received limited attention, it is now recognized as a persistent eating behaviour with important psychosocial implications. However, its associations with sleep quality, depressive symptoms, body mass index (BMI), and social appearance anxiety remain insufficiently investigated, especially in non-Western settings. This study explored the relationships between adult picky eating and these psychological and health-related variables among Turkish adults. METHODS: A cross-sectional study was conducted with 386 adults aged 18 years and older in Türkiye using an online snowball sampling method. Participants completed the Adult Picky Eating Questionnaire (APEQ), the Pittsburgh Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI), and the Social Appearance Anxiety Scale (SAAS). Sociodemographic information and BMI were also obtained. Between-group comparisons were performed using the Mann-Whitney U and Kruskal-Wallis tests. Spearman's rank correlation and multiple linear regression analyses were used to examine the associations and independent correlates of picky eating. RESULTS: In multivariable linear regression analysis, social appearance anxiety showed a modest, independent positive association with picky eating (B = 0.103, β = 0.201, p < 0.001), whereas BMI exhibited a weak inverse association (B = -0.176, β = -0.121, p = 0.033). Depressive symptoms and sleep quality were not independently associated with total picky eating scores. The overall model explained 7.7% of the variance. Exploratory bivariate correlations indicated a modest positive relationship between social appearance anxiety and total APEQ scores (ρ = 0.264, p < 0.001) with similar patterns observed across subscales, while associations involving depressive symptoms and sleep quality were largely weak or non-significant. CONCLUSIONS: In this adult sample, picky eating showed a modest positive association with social appearance anxiety and a weak inverse association with body mass index, whereas depressive symptoms and overall sleep quality were not independently associated. These observational findings suggest that appearance-related concerns may be relevant to individual variations in adult picky eating. However, the cross-sectional design, the low explanatory power of the multivariable model (R = 0.077), and the modest internal consistency of the APEQ require cautious interpretation and preclude causal, physiological, or clinical inferences. Future prospective studies incorporating comprehensive assessments of sensory sensitivity, food neophobia, body image, and dietary intake are needed to clarify the temporal and contextual factors associated with adult picky eating.

Acta psychologica 2026 Oct 17 PubMed
26 Interventional Pain Medicine for Women's Health 10.1093/med/9780197820476.001.0001 Unknown Journal 2026 Scholar
27 DEPRESSION AND ANXIETY IN ADULTS WITH STAGE 5 CHRONIC KIDNEY DISEASE RECEIVING RENAL REPLACEMENT THERAPY: A SYSTEMATIC REVIEW J. S. Arum et al. 10.21776/ub.jppbr.2026.007.02.9 Journal of Psychiatry Psychology and Behavioral Research 2026 Scholar
28 The relationship between mental health disorders and LUTS. J. Janssen et al. 10.1016/j.autneu.2026.103422 2 citations Autonomic neuroscience : basic & clinical 2026 Scholar
29 Exploring the role of pain catastrophizing in anxiety and depression among breast cancer survivors Reza Akbarzade et al. 10.4103/jehp.jehp_212_25 Journal of Education and Health Promotion 2026 Scholar
30 Informant discrepancies in adolescent anxiety assessment: The roles of adolescent depression and school avoidance. Blair D. Batky et al. 10.1037/pas0001503 Psychological assessment 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Mental Health & Depression
  • Week: October 12 – October 19, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:16 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —